Physician profile
Amro Elshoury
NPI 1417398975
$211,801.28
in general payments reported to CMS, 2019-2025
10 companies · $2,464 in 2025
The $2,464 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,113 · 2021: $456 · 2022: $33K · 2023: $66K · 2024: $107K · 2025: $2,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $154K · Travel and Lodging: $19K · Food and Beverage: $2,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $153,866.00 |
| Travel and Lodging | $19,326.22 |
| Food and Beverage | $2,652.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $209,105.26 | 2022-2025 | Ayvakit |
| Celgene Corporation | $1,662.50 | 2020 | |
| Akebia Therapeutics INC | $450.00 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $433.33 | 2021 | |
| Biomarin Pharmaceutical INC. | $45.50 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.63 | 2022 | |
| Pfizer INC. | $26.06 | 2022 | |
| Agios Pharmaceuticals, INC. | $23.76 | 2022 | |
| Servier Pharmaceuticals LLC | $22.24 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amro Elshoury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.